Inhibitors

Lupkynis; Luveniq; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-Ethyl-33-[(1R,2R,4E)-1-Hydroxy-2-Methylhepta-4,6-Dienyl]-1,4,7,10,12,15,19,25,28-Nonamethyl-6,9,18,24-Tetrakis(2-Methylpropyl)-3,21-di(Propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-Undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-Undecone; Voclera; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-Ethyl-33-((1R,2R,E)-1-Hydroxy-2-Methylhepta-4,6-dien-1-yl)-6,9,18,24-Tetraisobutyl-3,21-Diisopropyl-1,4,7,10,12,15,19,25,28-Nonamethyl-1,4,7,10,13,16,19,22,25,28,31-Undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-Undecaone; Cyclosporin A, 6-((2S,3R,4R)-3-Hydroxy-4-Methyl-2-(Methylamino)-6,8-Nonadienoic acid)-; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-Ethyl-33-[(1R,2R,4E)-1-Hydroxy-2-Methylhepta-4,6-dien-1-yl]-1,4,7,10,12,15,19,25,28-Nonamethyl-6,9,18,24-Tetrakis(2-Methylpropyl)-3,21-bis(Propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-Undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-Undecone; 1,11-Anhydro[L-Alanyl-D-Alanyl-N-Methyl-L-Leucyl-N-Methyl-L-Leucyl- N-Methyl-L-Valyl-[(2S,3R,4R,6E)-3-Hydroxy-4-Methyl- 2-(Methylamino)nona-6,8-Dienoyl][(2S)-2-Aminobutanoyl]- N-Methylglycyl-N-Methyl-L-Leucyl-L-Valyl-N-Methyl-L-Leucine]; Cyclo (((E,Z)-(2S,3R,4R)-3-Hydroxy-4-Methyl-2-(Methylamino)NONA-6,8-Dienoyl)-L-2-Aminobytyrl-N-Methyl-Glycyl-N-Methyl-L-Leucyl-L-Valyl-N-Methyl-L-Leucyl-L-Alanyl-D-Alanyl-N-Methyl-L-Leucyl-N-Methyl-L-Leucyl-N-Methyl-L-Valyl); Cyclo(L-Alanyl-D-Alanyl-N-Methyl-L-Leucyl-N-Methyl-L-Leucyl-N-Methyl-L-Valyl- ((2S,3R,4R,6E)-3-Hydroxy-4-Methyl-2-(Methylamino)NONA-6,8-Dienoyl)-(2S)-2- Aminobutanoyl-N-Methylglycyl-N-Methyl-L-Leucyl-L-Valyl-N-Methyl-L-Leucyl); Cyclosporin A, 6-((2S,3R,4R,6E)-3-Hydroxy-4-Methyl-2-(Methylamino)-6,8- Nonadienoic ACID)-

Trilaciclib Dihydrochloride; Trilaciclib 2HCl; G1T28 Hydrochloride; G1T28 Dihydrochloride; Trilaciclib (Hydrochloride); 2'-((5-(4-Methylpiperazin-1-yl)Pyridin-2-yl)Amino)-7',8'-Dihydro-6'Hspiro(Cyclohexane-1,9'-Pyrazino(1',2':1,5)Pyrrolo(2,3-d)Pyrimidin)-6'-one Dihydrochloride; 4-[[5-(4-Methylpiperazin-1-yl)Pyridin-2-yl]Amino]Spiro[1,3,5,11-Tetrazatricyclo[7.4.0.02,7]Trideca-2,4,6,8-Tetraene-13,1'-Cyclohexane]-10-one;Dihydrochloride; Spiro(Cyclohexane-1,9'(6'H)-Pyrazino(1',2':1,5)Pyrrolo(2,3-d)Pyrimidin)-6'-one, 7',8'-Dihydro-2'-((5-(4-Methyl-1-Piperazinyl)-2-Pyridinyl)Amino)-, Hydrochloride (1:2); Trilaciclib Hydrochloride(G1T28); 12'-{[5-(4-Methylpiperazin-1-yl)Pyridin-2-yl]Amino}-2',5',11',13'-Tetraazaspiro[Cyclohexane-1,3'-Tricyclo[7.4.0.0(2),]Tridecane]-1'(9'),7',10',12'-Tetraen-6'-one Dihydrochloride

SLx-2119; Belumosudil; KD-025; KD025; Rezurock; SLx 2119; 2-[3-[4-(1H-Indazol-5-Ylamino)Quinazolin-2-yl]Phenoxy]-N-Propan-2-Ylacetamide; Acetamide, 2-(3-(4-(1H-Indazol-5-Ylamino)-2-Quinazolinyl)Phenoxy)-N-(1-Methylethyl)-; 2-(3-(4-(1H-Indazol-5-Ylamino)Quinazolin-2-yl)Phenoxy)-N-Isopropylacetamide; 2-[3-[4-(1~{H}-Indazol-5-Ylamino)Quinazolin-2-yl]Phenoxy]-~{N}-Propan-2-yl-Ethanamide; 2-[3-[4-(1H-Indazol-5-Ylamino)-2-Quinazolinyl]Phenoxy]-N-(1-Methylethyl)-Acetamide; 2-(3-{4-[(1H-Indazol-5-yl)Amino]Quinazolin-2-yl}Phenoxy)-N-(Propan-2-yl)Acetamide; 2-[3-[4-(1H-Indazol-5-Ylamino)-2-Quinazolinyl]Phenoxy]-N-(1-Methylethyl)Acetamide

Elacestrant Hydrochloride; RAD1901 Dihydrochloride; RAD1901 Hydrochloride; RAD-1901 Dihydrochloride; Elacestrant (Dihydrochloride); 1349723-93-8 (HCl); (R)-6-(2-(Ethyl(4-(2-(Ethylamino)Ethyl)Benzyl)Amino)-4-Methoxyphenyl)-5,6,7,8-Tetrahydronaphthalen-2-ol Dihydrochloride; Elacestrant 2HCl; 2-Naphthalenol, 6-(2-(Ethyl((4-(2-(Ethylamino)Ethyl)Phenyl)Methyl)Amino)-4-Methoxyphenyl)-5,6,7,8-Tetrahydro-, Hydrochloride (1:2), (6R)-; Elacestrant (RAD1901) Dihydrochloride; (6r)-6-(2-(N-(4-(2-(Ethylamino)Ethyl)Benzyl)-N-Ethylamino)-4-Methoxyphenyl)5,6,7,8-Tetrahydronaphthalen-2-ol Dihydrochloride; (6R)-6-[2-[Ethyl-[[4-[2-(Ethylamino)Ethyl]Phenyl]Methyl]Amino]-4-Methoxyphenyl]-5,6,7,8-Tetrahydronaphthalen-2-ol;Dihydrochloride

NKTR-118 Oxalate; Naloxegol (Oxalate); AZ13337019 Oxalate; AZ-13337019 Oxalate; Naloxegol Oxalate(NKTR-118); Moventig; (4R,4aS,7S,7aR,12bS)-7-[2-[2-[2-[2-[2-[2-(2-Methoxyethoxy)Ethoxy]Ethoxy]Ethoxy]Ethoxy]Ethoxy]Ethoxy]-3-prop-2-enyl-1,2,4,5,6,7,7a,13-Octahydro-4,12-Methanobenzofuro[3,2-e]Isoquinoline-4a,9-diol;Oxalic acid; Movantik; 4,5Alpha-Epoxy-6Alpha-((3,6,7,12,15,18,21-Heptaoxadocosyl)oxy)-17-(prop-2-enyl)Morphinan-3,14-diol Hydrogen Ethanedioate; 4,5Alpha-Epoxy-6Alpha-[(3,6,7,12,15,18,21-Heptaoxadocosyl)oxy]-17-(prop-2-enyl)Morphinan-3,14-diol Hydrogen Ethanedioate; NKTR-118-Oxalate; NKTR-118;AZ-13337019 Oxalate; Movantik Component Naloxegol Oxalate; Naloxegol Oxalate Component OF Movantik; Morphinan-3,14-DIOL, 4,5-Epoxy-6-(3,6,9,12,15,18,21-Heptaoxadocos-1-Yloxy)-17-(2-Propen-1-YL)-, (5.Alpha.,6.Alpha.)-, Ethanedioate (1:1); Morphinan-3,14-diol, 4,5-Epoxy-6-(3,6,9,12,15,18,21-Heptaoxadocos-1-Yloxy)-17-(2-Propen-1-yl)-, (5Alpha,6Alpha)-, Ethanedioate (1:1)